alexa Perioperative NSAIDs May Reduce Early Relapses In Breast Cancer: Perhaps Transient Systemic Inflammation Plays A Role
ISSN: 2161-1025

Translational Medicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd International Conference on Translational Medicine
November 03-05, 2014 Las Vegas, USA

Michael Retsky
Accepted Abstracts: Transl Med
DOI: 10.4172/2161-1025.S1.014
While there have been important improvements in recent years, a general method to prevent relapses from early stage cancer is one of the most important unsolved problems in oncology. Author and his colleagues have been studying a bimodal pattern of hazard of relapse among early stage breast cancer patients that has been identified in multiple databases from US, Europe and Asia. In order to explain early relapse, they postulated that something happens at about the time of surgery to provoke sudden exits from dormant phases to active growth and then to detection. Most relapses in breast cancer are early. Recent data suggest an unexpected mechanism. A retrospective analysis of results from 327 consecutive breast cancer patients was conducted comparing various perioperative analgesics and anesthetics. A common NSAID analgesic used in surgery produced far superior disease-free survival in the first 5 years after surgery. The expected prominent early relapse events in months 9-18 are reduced 5-fold. If these observations hold up to further scrutiny, it could mean that the use of inexpensive and non-toxic anti-inflammatory agents at surgery might eliminate early relapses. Transient systemic inflammation accompanying surgery (identified by markers in serum) could facilitate angiogenesis of dormant micrometastases, proliferation of dormant single cells, and seeding of circulating tumor cells (perhaps in part released from bone marrow) resulting in early relapse and could have been effectively blocked by the perioperative anti-inflammatory agent.
Michael Retsky (PhD in Physics from University of Chicago) made a career change from physics to cancer research. He is Editor-in-Chief of Journal of Bioavailability and Bioequivalence, on staff at Harvard School of Public Health, honorary faculty at University College London, and Professor Adj. at UANL, Monterrey, Mexico. He was on Judah Folkman?s staff at Harvard Medical School for 12 years. He is on the board of directors of the Colon Cancer Alliance and has published more than 60 papers in physics and cancer. He has a patent pending for treatment of early stage cancer.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version